294.70 0.00 (0.00%)
After hours: 4:40PM EST
|Bid||294.52 x 800|
|Ask||301.28 x 800|
|Day's range||287.22 - 300.64|
|52-week range||118.55 - 388.97|
|Beta (5Y monthly)||0.86|
|PE ratio (TTM)||N/A|
|Earnings date||07 Aug 2018 - 13 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||320.58|
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that a supplemental Biologics License Application (sBLA) for anti-PD1 antibody tislelizumab was accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for treatment in the second- or third-line setting of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on prior platinum-based chemotherapy.
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
Market forces rained on the parade of BeiGene, Ltd. ( NASDAQ:BGNE ) shareholders today, when the analysts downgraded...